CGP 77675

belongs to class of substituted 5,7-diphenyl-pyrrolo(2,3-d)pyrimidines; structure in first source

Also Known As:

1-(2-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)phenyl)ethyl)-4-piperidinol(C119957 - M000636242); CGP-77675; CGP77675; 4-piperidinol, 1-(2-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)phenyl)ethyl)-

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - CGP 77675: 5
  - Pyrimidines: 510
    - CGP 77675: 5

Experts

1.	Rucci, Nadia: 1 article (04/2008)
2.	Susa, Maria: 1 article (04/2008)
3.	Teti, Anna: 1 article (04/2008)
4.	Dubner, Ronald: 1 article (10/2004)
5.	Guo, Wei: 1 article (10/2004)
6.	Ikeda, Tetsuya: 1 article (10/2004)
7.	Ren, Ke: 1 article (10/2004)
8.	Robbins, Meredith T: 1 article (10/2004)
9.	Sugiyo, Shinichi: 1 article (10/2004)
10.	Tu, Jian-Cheng: 1 article (10/2004)

Related Diseases

1.	Bone Resorption 05/01/1999 - "The effect of CGP77675 on bone resorption was evaluated in vitro and in vivo. " 05/01/1999 - "CGP77675 dose-dependently reduced the hypercalcemia induced in mice by interleukin-1beta and partly prevented bone loss and microarchitectural changes in young ovariectomized rats, showing that the protective effect on bone was exerted via the inhibition of bone resorption. " 05/01/1999 - "Here, we describe a novel class of Src inhibitors, substituted 5,7-diphenyl-pyrrolo[2,3-d]pyrimidines, and characterize one of them, CGP77675, in vitro and in models of bone resorption in vivo. " 04/01/2008 - "The pyrrolo-pyrimidines CGP77675 and CGP76030 proved to be effective in preventing bone loss in animal models, while the effect of AZD0530, a dually active inhibitor of c-Src and Bcr-ABL, on bone resorption, has been tested in a Phase I clinical trials with promising results. "
2.	Shock 01/01/2001 - "Using a pharmacological inhibitor of Src kinases CGP77675 and cells with knockout c-src, it was shown that Src activated STAT1 upon stimulation by both epidermal growth factor and hypersomatic shock. "
3.	Inflammation (Inflammations) 10/13/2004 - "Here, we show that in rats with Freund's adjuvant-induced inflammation, the increased dorsal horn NR2B tyr-P is blocked by group I metabotropic glutamate receptor (mGluR) antagonists [7-(hydroxyimino)cyclopropa[b] chromen-1a-carboxylate ethyl ester (CPCCOEt) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP), by the Src inhibitor CGP 77675, but not by the MAP kinase inhibitor 2'-amino-3'-methoxyflavone. "
4.	Hypercalcemia (Milk Alkali Syndrome) 05/01/1999 - "CGP77675 dose-dependently reduced the hypercalcemia induced in mice by interleukin-1beta and partly prevented bone loss and microarchitectural changes in young ovariectomized rats, showing that the protective effect on bone was exerted via the inhibition of bone resorption. "
5.	Carcinoma (Carcinomatosis) 09/01/2003 - "Two bona fide c-Src inhibitors, denominated CGP77675 and CGP76030, reduced in a time- and concentration-dependent manner (i) the proliferation of the PC3 prostate carcinoma cell line, as assessed by the [3H]-thymidine incorporation test, (ii) the capacity of PC3 cells to adhere and spread on Matrigel substrate, as determined by crystal violet staining, (iii) the ability of PC3 cells to migrate through a gelatine boundary and invade a Matrigel substrate. "

Related Drugs and Biologics

1.	Pyrimidines
2.	CGP 76030
3.	saracatinib
4.	Interleukin-1beta (Interleukin 1 beta)
5.	src-Family Kinases
6.	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
7.	Thymidine
8.	Phosphotransferases (Kinase)
9.	Gentian Violet (Violet, Crystal)
10.	Freund's Adjuvant